Therapeutic effects of tofacitinib on steroid-resistant immune checkpoint inhibitor-associated myocarditis

Background and purpose: Outcomes for cancer patients with steroid-resistant immune checkpoint inhibitor-associated myocarditis (srICIAM) are poor. Intensified immunosuppressive therapies, including tofacitinib, a novel Janus kinase (JAK) inhibitor, may have some therapeutic benefits. However, due to...

Full description

Bibliographic Details

Published in:	Zhongguo aizheng zazhi
Main Author:	XU Yuchen, ZHANG Jian, WANG Yan, LIN Jinyi, ZHOU Yuhong, CHENG Leilei, GE Junbo
Format:	Article
Language:	English
Published:	Editorial Office of China Oncology 2024-04-01
Subjects:	|immune checkpoint inhibitors|immunotherapy|myocarditis|janus kinase inhibitor
Online Access:	http://www.china-oncology.com/fileup/1007-3639/PDF/1715926479961-1835987623.pdf